Vito Terlizzi
Overview
Explore the profile of Vito Terlizzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conti J, Angyal D, Kleinfelder K, Latorre R, Calicchia M, Farinazzo A, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40023749
No abstract available.
2.
Conti J, Angyal D, Kleinfelder K, Latorre R, Calicchia M, Farinazzo A, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39979195
Introduction: Cystic fibrosis (CF) is caused by mutation of the CFTR gene, encoding an epithelial anion channel. Here we evaluated the effect of the modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) on the...
3.
Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G, et al.
Ther Adv Respir Dis
. 2025 Feb;
19:17534666251314706.
PMID: 39930791
Background: Cystic fibrosis (CF) is characterized by chronic neutrophilic inflammation in the airways. Elexacaftor/tezacaftor/ivacaftor (ETI) therapy has demonstrably improved clinical outcomes and quality of life in people with CF (pwCF),...
4.
Terlizzi V, Fevola C, Presti S, Claut L, Ambroni M, Calderazzo M, et al.
Pediatr Pulmonol
. 2025 Jan;
60(1):e27483.
PMID: 39812351
Background: Notwithstanding guidance from the European Cystic Fibrosis (CF) Society (ECFS) neonatal screening (NBS) working group, significant variation persists in the evaluation and management of Cystic Fibrosis Screen Positive, Inconclusive...
5.
Terlizzi V, Fevola C, Cecchetti M, Terminiello A, Curci F, Bartolini E, et al.
J Cyst Fibros
. 2025 Jan;
PMID: 39800644
Background: Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved the clinical course of people with cystic fibrosis (pwCF) and eligible CFTR variants. In this study, we prospectively evaluated liver elastography, liver fibrosis indices...
6.
Taccetti G, Terlizzi V, Campana S, Dolce D, Ravenni N, Fevola C, et al.
Eur J Pediatr
. 2024 Dec;
184(1):82.
PMID: 39672981
Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections...
7.
Tomati V, Capurro V, Pesce E, Pastorino C, Sondo E, Lena M, et al.
Front Pharmacol
. 2024 Dec;
15:1494327.
PMID: 39624835
Introduction: Cystic Fibrosis (CF) is a genetic disease due to loss-of-function mutations of the CFTR channel. F508del is the most frequent mutation (70% of alleles in Italy), while other mutations...
8.
Terlizzi V, Fevola C, Castaldo A, Vespa S, Dolce D, Scarallo L, et al.
BMC Pediatr
. 2024 Nov;
24(1):752.
PMID: 39567905
While Cystic Fibrosis is characterized by a high phenotypic variability, a correlation is reported between the pancreatic status and the CFTR genotype. Here we report an unusual case of a...
9.
Marsiglia R, Pane S, Del Chierico F, Russo A, Vernocchi P, Romani L, et al.
Microorganisms
. 2024 Oct;
12(10).
PMID: 39458368
infection (CDI) is generally treated with vancomycin, metronidazole or fidaxomicin, although fecal microbiota transplantation (FMT) represents a promising therapeutic option for antibiotic-resistant recurrent infections (rCDIs) in adults. In pediatric cystic...
10.
Montresor A, DUlivo B, Preato S, Farinazzo A, Pintani E, Chiara E, et al.
Am J Respir Cell Mol Biol
. 2024 Oct;
71(4):495-498.
PMID: 39352210
No abstract available.